Home > Support > Customer Publications

Customer Publications

de Vries F, Franssen EJF, Smit AAJ, et al. TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation. Clin Pharmacokinet. 2025;64(10):1507-1515. doi:10.1007/s40262-025-01555-8

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic–Pharmacoeconomic Evaluation

Product recommends: Durvalumab ELISA Kit purchased from abinScience
Simon Streif Universität Regensburg, 2025 Development of Liposome-based Sensing Strategies for Clinical Diagnostics

Development of liposome-based sensing strategies for clinical diagnostics

Product recommends: SARS-CoV-2 Surrogate Virus Neutralization Test Kit purchased from abinScience
Qiu S‑F, Chen Z, Zhu A‑R, et al. Successful clearance of persistent SARS‑CoV‑2 asymptomatic infection following a single dose of Ad5‑nCoV vaccine. Signal Transduct Target Ther. 2023;8:123. doi:10.1038/s41392-023-01345-3

Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine

Product recommends: Anti-SARS-CoV-2 Spike Protein (Trimer) Human IgG ELISA Kit purchased from abinScience
Pan Y, Du J, Liu J, et al. Screening of potent neutralizing antibodies against SARS‑CoV‑2 using convalescent patients‑derived phage‑display libraries. Cell Discov. 2021;7:57. doi:10.1038/s41421-021-00295-w

Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries

Product recommends: SARS-CoV-2 Surrogate Virus Neutralization Test Kit purchased from abinScience
Zhou Y, Lu X, Wang X, Ying T, Tan X. Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity. Int J Mol Sci. 2023;24(4):4068. Published 2023 Feb 17. doi:10.3390/ijms24044068

Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity

Product recommends: SARS-CoV-2 Surrogate Virus Neutralization Test Kit (Omicron) purchased from abinScience
Tang H, Gao L, Wu Z, et al. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. Front Immunol. 2022;13:836232. Published 2022 Mar 16. doi:10.3389/fimmu.2022.836232

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

Product recommends: SARS-CoV-2 RBD (JN.1) ELISA Kit purchased from abinScience
Qiu S‑F, Chen Z, Zhu A‑R, et al. Successful clearance of persistent SARS‑CoV‑2 asymptomatic infection following a single dose of Ad5‑nCoV vaccine. Signal Transduct Target Ther. 2023;8:123. doi:10.1038/s41392-023-01345-3

Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine

Product recommends: Anti-SARS-CoV-2 Spike Protein (Trimer) Human IgG ELISA Kit purchased from abinScience
Pan Y, Du J, Liu J, et al. Screening of potent neutralizing antibodies against SARS‑CoV‑2 using convalescent patients‑derived phage‑display libraries. Cell Discov. 2021;7:57. doi:10.1038/s41421-021-00295-w

Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries

Product recommends: SARS-CoV-2 Surrogate Virus Neutralization Test Kit purchased from abinScience
Zhou Y, Lu X, Wang X, Ying T, Tan X. Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity. Int J Mol Sci. 2023;24(4):4068. Published 2023 Feb 17. doi:10.3390/ijms24044068

Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity

Product recommends: SARS-CoV-2 Surrogate Virus Neutralization Test Kit (Omicron) purchased from abinScience
Tang H, Gao L, Wu Z, et al. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. Front Immunol. 2022;13:836232. Published 2022 Mar 16. doi:10.3389/fimmu.2022.836232

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

Product recommends: SARS-CoV-2 RBD (JN.1) ELISA Kit purchased from abinScience

Get a free quote